Improved Quality of Life in Men With Prostate Cancer Receiving Abiraterone Compared With Docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
J. Clin. Oncol 2021 Nov 10;[EPub Ahead of Print], HL Rush, L Murphy, AK Morgans, NW Clarke, AD Cook, G Attard, A Macnair, DP Dearnaley, CC Parker, JM Russell, S Gillessen, D Matheson, R Millman, CD Brawley, C Pugh, JS Tanguay, RJ Jones, J Wagstaff, S Rudman, JM O'Sullivan, J Gale, A Birtle, A Protheroe, E Gray, C Perna, S Tolan, N McPhail, ZI Malik, S Vengalil, D Fackrell, P Hoskin, MR Sydes, S Chowdhury, DC Gilbert, MKB Parmar, ND James, RE LangleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.